Engineering NK Cells with High-Affinity CD16 for Enhanced Combination Therapy to Treat B-Cell Lymphoma
NK cells play a pivotal role in rapid and highly efficient cancer surveillance and represent a promising avenue for adoptive cell transfer either as a mono or combination immunotherapy.
Read MoreCRISPR Electroporation of T Cells Improves Treatment in Patients with Refractory Cancer
Cancer immunotherapy is a fast-moving field that blends cutting-edge technologies to overcome past obstacles in the clinic.
Read MoreTranslation of NK Cell CAR Therapy to the Clinic: Critical Role of Performance & Clinical-scalability
The prognosis for adult B-cell malignancies, such as acute lymphoblastic leukemia (ALL),1,2 non-Hodgkin lymphoma (NHL)3 and chronic lymphocytic leukemia (CLL),4 is poor, particularly for patients with refractory or relapsing disease. Recently, two breakthrough anti-CD19 CAR-T cell therapies were approved by the FDA for use in adults with specific relapsed or refractory B-cell malignancies.
Read MoreHematopoietic Stem Cell Electroporation for HDR-Mediated Correction of an X-Linked Blood Disorder
Wiskott-Aldrich Syndrome (WAS) is an X-linked recessive primary immunodeficiency affecting between 1 in 50,000 to 1 in 250,000 live births worldwide. Mutations in the WAS gene cause abnormal immune system function, thrombocytopenia, and an increased incidence of autoimmune malignancies.
Read More
